ES2166377T3 - Uso de vitamina d y derivados de la misma en la fabricacion de un medicamento para la proteccion contra la perdida de neuronas. - Google Patents

Uso de vitamina d y derivados de la misma en la fabricacion de un medicamento para la proteccion contra la perdida de neuronas.

Info

Publication number
ES2166377T3
ES2166377T3 ES94923484T ES94923484T ES2166377T3 ES 2166377 T3 ES2166377 T3 ES 2166377T3 ES 94923484 T ES94923484 T ES 94923484T ES 94923484 T ES94923484 T ES 94923484T ES 2166377 T3 ES2166377 T3 ES 2166377T3
Authority
ES
Spain
Prior art keywords
vitamin
compound
neuron loss
against neuron
protect against
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94923484T
Other languages
English (en)
Inventor
Philip W Landfield
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Kentucky
Original Assignee
University of Kentucky
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Kentucky filed Critical University of Kentucky
Application granted granted Critical
Publication of ES2166377T3 publication Critical patent/ES2166377T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
  • Signal Processing For Digital Recording And Reproducing (AREA)
  • Moving Of Heads (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE INVENCION CORRESPONDE A UN METODO DE PROTECCION CONTRA LA PERDIDA DE NEURONAS EN UN SUJETO MEDIANTE LA ADMINISTRACION DE UN COMPUESTO QUE PROTEGE CONTRA LA PERDIDA DE NEURONAS ACTUANDO A TRAVES DE UN RECEPTOR DE VITAMINA D. ALGUNOS DE ESTOS COMPUESTOS PUEDEN PREVENIR O RETARDAR LA PERDIDA DE NEURONAS MEDIANTE LA REGULACION DE LOS NIVELES DE CALCIO Y FOSFATO INTRANEURONAL Y/O PERIFERICO. OTROS COMPUESTOS DE LA INVENCION ACTUAN A TRAVES DE UN RECEPTOR DE VITAMINA D PARA PROTEGER CONTRA LA PERDIDA DE NEURONAS A TRAVES DE MECANISMOS QUE NO INCLUYEN LA REGULACION CALCIO O FOSFATO. UN COMPUESTO PREFERIDO ES UNA FORMA BIOLOGICAMENTE ACTIVA DE VITAMINA D, UN PRECURSOR, METABOLITO, O ANALOGO DE VITAMINA D. UNA FORMA PREFERIDA DE VITAMINA D ES CALCITRIOL. EN OTRA REALIZACION, EL COMPUESTO ES UN COMPUESTO QUE ACTUA MODULANDO LA ACTIVIDAD BIOLOGICA DE LA VITAMINA D, UN PRECURSOR, METABOLITO, O ANALOGO DE VITAMINA D. POR EJEMPLO, EL COMPUESTO PUEDE MODULAR LA ACTIVIDAD BIOLOGICA DEL COMPUESTO DE VITAMINA D MEDIANTE LA REGULACION DE LA CANTIDAD DEL COMPUESTO DE VITAMINA D QUE ESTA DISPONIBLE PARA PROTEGER CONTRA LA PERDIDA DE NEURONAS O PUEDE ACTUAR ALTERANDO LA CAPACIDAD DEL COMPUESTO DE VITAMINA D PARA PROTEGER CONTRA LA PERDIDA DE NEURONAS. EN UNA REALIZACION ALTERNATIVA, EL COMPUESTO ES UN COMPUESTO QUE PROTEGE CONTRA LA PERDIDA DE NEURONAS A TRAVES DE UN MECANISMO SIMILAR AL DEL COMPUESTO DE VITAMINA D PERO NO INCLUYE UN RECEPTOR DE VITAMINA D. EL COMPUESTO ES ADMINISTRADO A UN SUJETO EN UNA CANTIDAD Y SOBRE UN PERIODO DE TIEMPO EFECTIVO PARA PROTEGER CONTRA LA PERDIDA DE NEURONAS.
ES94923484T 1993-07-15 1994-07-14 Uso de vitamina d y derivados de la misma en la fabricacion de un medicamento para la proteccion contra la perdida de neuronas. Expired - Lifetime ES2166377T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9197693A 1993-07-15 1993-07-15

Publications (1)

Publication Number Publication Date
ES2166377T3 true ES2166377T3 (es) 2002-04-16

Family

ID=22230588

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94923484T Expired - Lifetime ES2166377T3 (es) 1993-07-15 1994-07-14 Uso de vitamina d y derivados de la misma en la fabricacion de un medicamento para la proteccion contra la perdida de neuronas.

Country Status (10)

Country Link
US (1) US5939407A (es)
EP (1) EP0710112B1 (es)
JP (1) JPH09507830A (es)
AT (1) ATE209921T1 (es)
AU (1) AU7333694A (es)
CA (1) CA2167171C (es)
DE (1) DE69429351T2 (es)
ES (1) ES2166377T3 (es)
IL (1) IL110309A0 (es)
WO (1) WO1995002409A2 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015075291A1 (es) * 2013-11-20 2015-05-28 Universidade De Santiago De Compostela Análogos de vitamina d con interés farmacéutico

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU728037B2 (en) * 1997-05-22 2001-01-04 Cephalon, Inc. Vitamin D analogues and their neuronal effects
IL139672A (en) * 1998-05-15 2005-11-20 Univ Leland Stanford Junior Glucocorticoid receptor antagonists for the tretment of dementia
WO2007115282A2 (en) * 2006-04-03 2007-10-11 Accera, Inc. Use of ketogenic compounds for treatment of age-associated memory impairment
AU2001261378B2 (en) * 2000-05-09 2005-03-17 Children's Medical Center Corporation Method and composition for the treatment of angiogenesis
US7858602B2 (en) * 2000-10-16 2010-12-28 Rodriguez Victorio C Therapeutic and prophylactic uses of cell specific carbonic anhydrase enzymes in treating aging disorders due to oxidative stress and as growth factors of stem cells
US7256184B2 (en) * 2000-10-16 2007-08-14 Rodriguez Victorio C Treatment of aging disorders in humans
DE60128251T2 (de) * 2000-11-03 2008-01-10 Washington University Östronderivate mit zellschützender wirkung
US20020132802A1 (en) * 2000-11-17 2002-09-19 Washington Univeristy Cytoprotective polycyclic compounds
WO2002096433A1 (en) * 2001-05-04 2002-12-05 Corcept Therapeutics, Inc. Methods for treating delirium using glucocorticoid receptor-specific antagonists
US20040053895A1 (en) * 2002-09-18 2004-03-18 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
US7148211B2 (en) * 2002-09-18 2006-12-12 Genzyme Corporation Formulation for lipophilic agents
US20040058895A1 (en) * 2002-09-18 2004-03-25 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
US20050192255A1 (en) * 2003-07-30 2005-09-01 Jin Tian Use of Vitamin Ds or Vitamin D analogs to treat cardiovascular disease
JP2008500368A (ja) * 2004-05-27 2008-01-10 ミジェニックス コーポレイション 細胞保護のための２置換１７−イミノエストロゲン化合物
EP1893576A4 (en) * 2005-05-27 2010-03-17 Univ Kingston TREATMENT OF PROTEIN DISORDERING
JP2007023010A (ja) * 2005-07-19 2007-02-01 Toshiro Azegami 閉経後のホルモンバランス調整及びパーキンソン症の予防改善目的の経口組成物
US20100204192A1 (en) * 2007-06-11 2010-08-12 University Of Sourthern California Agents, compositions and methods for enhancing neurological function
WO2008154579A1 (en) * 2007-06-11 2008-12-18 University Of Southern California Allopregnanolone in a method for enhancing neurological function (alzheimer disease)
WO2010088409A2 (en) * 2009-01-30 2010-08-05 Emory University Methods of neuroprotection using neuroprotective steroids and a vitamin d
EP2363119A1 (fr) * 2010-03-05 2011-09-07 Centre Hospitalier Universitaire d'Angers Nouvelle composition pharmaceutique utile pour le traitement des personnes affectées par des maladies neurodégénératives ou neurovasculaires
FR2965178B1 (fr) * 2010-09-29 2012-10-05 Sebastien Lasnier Composition pharmaceutique utilise dans le traitement de la maladie d'alzheimer
HRP20230747T1 (hr) 2011-09-08 2024-01-05 Sage Therapeutics, Inc. Neuroaktivni steroidi, pripravci i njihova uporaba
SMT201800657T1 (it) 2013-03-13 2019-01-11 Sage Therapeutics Inc Steroidi neuroattivi e loro metodi di utilizzo
US20140296190A1 (en) * 2013-03-27 2014-10-02 Dsm Ip Assets B.V. Marketing the use of 25-hydroxyvitamin d3 to enhance cognition
HK1219208A1 (zh) * 2013-03-27 2017-03-31 帝斯曼知识产权资产管理有限公司 25-羟基维生素d3用於增强执行功能的用途
WO2015195967A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
AU2016289965B2 (en) 2015-07-06 2021-09-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
MX382122B (es) 2015-07-06 2025-03-13 Sage Therapeutics Inc Oxiesteroles y metodos de uso de los mismos.
PL3319611T3 (pl) 2015-07-06 2021-07-12 Sage Therapeutics, Inc. Oksysterole i sposoby ich stosowania
EP3436022B1 (en) 2016-04-01 2022-03-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US10752653B2 (en) 2016-05-06 2020-08-25 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
WO2018009867A1 (en) 2016-07-07 2018-01-11 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
PT3519422T (pt) 2016-09-30 2022-12-05 Sage Therapeutics Inc Oxisteróis substituídos em c7 e métodos como moduladores nmda
DK4105223T3 (da) 2016-10-18 2025-07-07 Sage Therapeutics Inc Oxysteroler og fremgangsmåder til anvendelse deraf
CA3041088C (en) 2016-10-18 2024-05-21 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
CA3176523A1 (en) 2020-04-24 2021-10-28 The Johns Hopkins University Compositions and methods comprising dendrimers and therapeutic agents
WO2023028554A1 (en) 2021-08-25 2023-03-02 Neuraly, Inc. Glp-1r agonists for use in a treatment of neurological impairment associated with viral infection

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63104926A (ja) * 1986-10-21 1988-05-10 Teijin Ltd 老年性痴呆症治療又は予防剤
FR2639225B1 (fr) * 1988-11-21 1993-05-21 Centre Nat Rech Scient Compositions pharmaceutiques pour la neuroprotection contenant des arylcyclohexylamines
US4897388A (en) * 1988-12-20 1990-01-30 Geriatric Research Institute, Inc. Method of treating Alzheimer's disease
US4957909A (en) * 1989-05-04 1990-09-18 American Home Products Corporation Benzobicycloalkane derivatives as anticonvulsant neuroprotective agents
US5089517A (en) * 1990-08-03 1992-02-18 The Board Of Trustees Of The Leland Stanford Junior University Neuroprotection by indolactam v and derivatives thereof
US5168103A (en) * 1991-01-22 1992-12-01 American Home Products Corporation [[2-(amino-3,4-dioxo-1-cyclobuten-1-yl) amino]alkyl]-acid derivatives
US5153196A (en) * 1991-06-05 1992-10-06 Eli Lilly And Company Excitatory amino acid receptor antagonists and methods for the use thereof
US5196421A (en) * 1991-06-05 1993-03-23 Eli Lilly And Company Excitatory amino acid receptor antagonists in methods for the use thereof

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015075291A1 (es) * 2013-11-20 2015-05-28 Universidade De Santiago De Compostela Análogos de vitamina d con interés farmacéutico
US9663429B2 (en) 2013-11-20 2017-05-30 Universidade De Santiago De Compostela Vitamin D analogues of pharmaceutical interest

Also Published As

Publication number Publication date
US5939407A (en) 1999-08-17
WO1995002409A3 (en) 1995-04-27
ATE209921T1 (de) 2001-12-15
DE69429351T2 (de) 2002-05-23
AU7333694A (en) 1995-02-13
DE69429351D1 (de) 2002-01-17
CA2167171A1 (en) 1995-01-26
WO1995002409A2 (en) 1995-01-26
CA2167171C (en) 2007-04-24
IL110309A0 (en) 1994-10-21
EP0710112A1 (en) 1996-05-08
JPH09507830A (ja) 1997-08-12
EP0710112B1 (en) 2001-12-05

Similar Documents

Publication Publication Date Title
ES2166377T3 (es) Uso de vitamina d y derivados de la misma en la fabricacion de un medicamento para la proteccion contra la perdida de neuronas.
ATE286384T1 (de) Formulierung mit verzögerter freisetzung enthaltend kollagen und glykosaminoglykan
MD895B2 (ro) Preparat sinergetic şi procedeu de distrugere selectivă a buruienilor
DE69940557D1 (de) Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung
UA35604C2 (uk) Фармацевтична композиція з антидепресивною активністю
ES2098920T3 (es) Formulaciones farmaceuticas para el tratamiento de la dependencia a la nicotina.
UY24308A1 (es) Tabletas exentas de aglutinante que contienen tramadol o una sal de tramadol, para administracion oral
DK0498636T3 (da) Kosmisk sammensætning
Marks Jr Treatment of apocrine chromhidrosis with topical capsaicin
EP0620004A4 (en) MEDICAL COMPOSITION.
EP0714304B1 (de) Therapeutisches system zur behandlung der psoriasis
HUP9901686A2 (hu) Fungicid keverékek
NO994395L (no) Stabilt, fast preparat som inneholder vitamin D3 og trikalsiumfosfat
CA2158952A1 (en) 2-substituted morpholine and thiomorpholine derivatives as gaba-b antagonists
ATE158947T1 (de) Hautregenerierende kosmetische zusammensetzung
EE03524B1 (et) Vahend diabeedi komplikatsioonide profülaktikaks ja raviks
BR9707770C1 (pt) Tifluzamida com eficácia aperfeiçoada
DE3573707D1 (de) Anticoccidial compostions
ATE169819T1 (de) (-)-metrifonat enthaltendes arzneimittel
ES2078319T3 (es) Composiciones que contienen inhibidores de aldosa reductasa para el tratamiento de ulceras.
DE69307197D1 (de) Verwendung von 24,25-Dihydroxyvitamin-D3 zur Herstellung eines Arzneimittel zur Behandlung der Rachitis
HU9402698D0 (en) Pharmaceutical composition for treating climacteric osteoporosis
FR2759586B1 (fr) Medicament de type anticancereux comportant au moins a titre de principe actif du 1-alpha hydroxycalciferol ou alfacalcidol
KR950007852A (ko) 우라실을 유효성분으로 함유하는 관절염 치료제
MX9400288A (es) Procedimiento para la preparacion de un medicamento util como radiorestaurador.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 710112

Country of ref document: ES